Last reviewed · How we verify
Imprimis Less Drops — Competitive Intelligence Brief
marketed
Compounded ophthalmic anti-inflammatory/lubricant
Ophthalmology
Small molecule
Live · refreshed every 30 min
Target snapshot
Imprimis Less Drops (Imprimis Less Drops) — Eye Center of North Florida. Imprimis Less Drops is a compounded ophthalmic formulation designed to reduce ocular surface inflammation and provide symptomatic relief in dry eye disease.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Imprimis Less Drops TARGET | Imprimis Less Drops | Eye Center of North Florida | marketed | Compounded ophthalmic anti-inflammatory/lubricant |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Compounded ophthalmic anti-inflammatory/lubricant class)
- Eye Center of North Florida · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Imprimis Less Drops CI watch — RSS
- Imprimis Less Drops CI watch — Atom
- Imprimis Less Drops CI watch — JSON
- Imprimis Less Drops alone — RSS
- Whole Compounded ophthalmic anti-inflammatory/lubricant class — RSS
Cite this brief
Drug Landscape (2026). Imprimis Less Drops — Competitive Intelligence Brief. https://druglandscape.com/ci/imprimis-less-drops. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab